Click the hypertext link to download copies of the HESI presentations.
Assembly of Members Session
Introduction to HESI Portfolio
Dr. James MacDonald, Schering-Plough Research Institute
Application of Genomics to Mechanism-Based Risk Assessment
Ms. Syril Pettit, HESI
Developmental and Reproductive Toxicology
Dr. Dana Shuey, Endo Pharmaceuticals
Immunotoxicology
Mr. Karluss Thomas, HESI
Nonclinical/Clinical Safety Coorelations
Dr. Ed Kadyszewski, Pfizer
Protein Allergenicity
Dr. Laura Privalle, BASF Plant Science
Risk Assessment Methodology
Dr. Dennis Devlin, Exxon Biomedical Sciences Inc.
Bioaccumulation
Dr. Christina Cowan-Ellsberry, Procter & Gamble
Biological Significance of DNA Adducts
Dr. Gary Williams, New York Medical College
Cancer Hazard Identification Strategies
Prof. Alan Boobis, Imperial College of London
Cardiovascular Pro-Arrhythmia Models
Dr. Jean-Pierre Valentin, AstraZeneca
PPAR Agonist
Dr. Samuel Cohen, University of Nebraska Medical Center
Emerging Issues Session
Risks to Human and Ecological Health from Pharmaceuticals in the Environment
Dr. Hal Zenick, US Environmental Protection Agency
Dr. Richard Williams, Pfizer
Distinguishing Adverse from Adaptive, Non-functional and Pharmacological Changes in Toxicology Studies
Dr. William Farland, Colorado State University
Dr. Doug Keller, sanofi-aventis
Establishing Acceptable Exposure Limits for Intermittent or Short-Term Exposure to Carcinogens
Dr. Gary Williams, New York Medical College
Dr. Susan Felter, The Procter & Gamble Company
Drug Abuse Liability / Preclinical Abuse Liability Assessment
Dr. S. Stevens Negus, Virginia Commonwealth University
Dr. Mary Jeanne Kallman, Eli Lilly
Relevance and Follow-up of Positive Results in In Vitro Genetic Toxicology Testing
Dr. Bhaskar Gollapudi, The Dow Chemical Company
Risk Assessment for Sensitive Populations
Dr. Ronald Hines, Medical College of Wisconsin
Emergence of Animal Alternative Needs in Environmental Risk Assessment
Dr. Scott Belanger, Procter & Gamble
State of the Science: Evaluating Epigenetic Changes
Dr. Jay Goodman, Michigan State University
Use of Imaging Tools in Toxicology
Overview- Applicability/Feasibility of Rodent Imaging
Kathy Gabrielson, Johns Hopkins Medical Institutions
Translational Molecular Imaging: Focus on Radiopharmaceuticals
Martin G. Pomper, Johns Hopkins University
State of the Science Scientific Session
State of the Sciences Within HESI
Prof. Alan R. Boobis, Imperial College London
Development and Application of Biomarkers of Toxicity
Dr. Ernie Harpur, sanofi-aventis
Dr. Dana Walker, Bristol-Myers Squibb
Integration of Biomonitoring Exposure Data into the Risk Assessment Process
Dr. Steven Robison, The Procter & Gamble Company
Nanomaterial Environmental, Health, and Safety
Dr. Raymond David, BASF Corporation